These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 21811088

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
    Polyzos A, Felekouras E, Karatzas T, Griniatsos J, Dimitroulis D, Polyzos K, Kontzoglou K, Mantas D, Karavokyros J, Nikiteas N, Tsavaris N, Syrigos K, Vafiadis I.
    Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
    Amarantidis K, Xenidis N, Chelis L, Chiotis A, Tentes A, Chatzaki E, Kortsaris A, Polychronidis A, Karakitsos P, Kakolyris S.
    Acta Oncol; 2010 Sep; 49(2):245-51. PubMed ID: 19839918
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH, Oh SC, Kim JS, Nam SH, Kim BS, Cho SH, Chung IJ, Song EK, Yim CY, Baek JH, Jeung HC, Hong YS, Yang SH, Kang HJ.
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
    Liu Y, Ma T, Ye ZB, Zhang J, Zhu ZG.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Mar; 13(3):177-80. PubMed ID: 20336533
    [Abstract] [Full Text] [Related]

  • 11. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
    Evans D, Miner T, Akerman P, Millis R, Jean M, Kennedy T, Safran H.
    Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
    Kim JG, Sohn SK, Kim DH, Baek JH, Sung WJ, Park JY, Kim TB, Jung HY, Yu W, Lee KB.
    Oncology; 2005 Aug; 68(2-3):190-5. PubMed ID: 16006756
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V.
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [Abstract] [Full Text] [Related]

  • 15. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, Samonis G, Vardakis N, Amarantidis K, Agelaki S, Mavroudis D, Xenidis N, Georgoulias V.
    Oncology; 2004 Mar; 66(4):253-9. PubMed ID: 15218291
    [Abstract] [Full Text] [Related]

  • 16. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
    Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, Mavroudis D, Georgoulias V.
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
    [Abstract] [Full Text] [Related]

  • 17. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY, Cho JY, Oh KJ, Choi SH, Lee SI, Jeung HC.
    Chemotherapy; 2009 Feb; 55(4):200-6. PubMed ID: 19451710
    [Abstract] [Full Text] [Related]

  • 18. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
    Goel G, Jauhri M, Negi A, Aggarwal S.
    Hematol Oncol Stem Cell Ther; 2010 Feb; 3(2):55-9. PubMed ID: 20543537
    [Abstract] [Full Text] [Related]

  • 19. Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
    Liu C, Sun Q, Hang X, Zhong B, Wang D.
    Anticancer Drugs; 2008 Sep; 19(8):825-31. PubMed ID: 18690095
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
    Hong YS, Lee SS, Kim KP, Lee JL, Kang YK, Shin SJ, Ahn JB, Jung KH, Im SA, Kim TY, Kim JH, Park YS, Kim TW.
    Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.